Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

L
L. Zapata, Maycos

Latin American Cooperative Oncology Group
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Maycos L. Zapata
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Maycos L. Zapata
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Maycos L. Zapata
Favorite
La Ferlita, Alessandro

The Ohio State University
(P 136) TARGETING MIR-138-5P TO TREAT DEDIFFERENTIATED LIPOSARCOMA
Alessandro La Ferlita
Favorite
López Pousa, Antonio

Hospital Santa Creu Y Sant Pau
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Antonio López Pousa
Favorite
Laetsch, Theodore

The Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
(P 318) SYNOVIAL SARCOMA REGISTRY AND BIOSPECIMEN REPOSITORY: DESCRIBING THE COHORT AND SURVIVAL OUTCOMES TO DATE
Theodore Laetsch
Favorite
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Theodore Laetsch
Favorite
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Theodore Laetsch
Favorite
Laffi, Alice

Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Alice Laffi
Favorite
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Alice Laffi
Favorite
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Alice Laffi
Favorite
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Alice Laffi
Favorite
Lafontaine, Julie

Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Canada; Institut du Cancer de Montréal (ICM), Montréal, Canada
(P 326) CELL-FREE DNA AS A BIOMARKER FOR CELL DEATH AND TREATMENT RESPONSE IN ON-CHIP THREE-DIMENSIONAL SARCOMA TUMOR MODELS
Julie Lafontaine
Favorite
Laginestra, Maria Antonella

IRCCS Istituto Ortopedico Rizzoli
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Maria Antonella Laginestra
Favorite
Lagmay, Joanne

Shand's Hospital for Children at the University of Florida
(P 309) PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL IN PATIENTS WITH RECURRENT SOFT TISSUE SARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Joanne Lagmay
Favorite
Lake, Jessica

National Cancer Institute
(P 414) TENOSYNOVIAL GIANT CELL TUMOR IN CHILDREN: INTERIM RESULTS FROM A PHASE 1 STUDY OF TURALIO®
Jessica Lake
Favorite
Lakhani, Nehal

START Midwest
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Nehal Lakhani
Favorite
Lalezari, Jacob

Quest Clinical Research
(P 106) DELTAREX-G, A TUMOR TARGETED CCNG1 INHIBITOR, DEMONSTRATES CLINICAL BENEFIT IN ADVANCED CHEMORESISTANT SARCOMA FOLLOWING FDA CBER AUTHORIZATION FOR USE AS PLATFORM THERAPY WITH FDA APPROVED DRUGS
Jacob Lalezari
Favorite
Lalli, Luca

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Luca Lalli
Favorite
Lammers, Marshall

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Marshall Lammers
Favorite
Landers, Sharon

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Sharon Landers
Favorite
Lan, shijie

The First Hospital of Jilin University
(P 119) UPDATED RESULTS OF A SINGLE-ARM,MULTI-CENTER STUDY OF ANLOTINIB COMBINED WITH TORIPALIMAB IN FIRST-LINE TREATMENT OF UNRESECTABLE OR METASTATIC UNDIFFERENTIATED PLEOMORPHIC SARCOMA
shijie Lan
Favorite
Lanza, Ezio

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Ezio Lanza
Favorite
Lapp, Sean

USF Health Morsani College of Medicine
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Sean Lapp
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Sean Lapp
Favorite
Lara, Camila

Hospital Israelita Albert Einstein
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Camila Lara
Favorite
Lara, Kristi

Department of Internal Medicine, Keck School of Medicine of USC Division of Medical Oncology
(P 158) RECURRENT RADIATION-INDUCED SARCOMA IN A PATIENT WITH HEREDITARY RETINOBLASTOMA: PRESENTATION AND OUTCOME
Kristi Lara
Favorite
Latour, Emile

OHSU
(P 364) A PHASE 1B TRIAL OF PREOPERATIVE ERIBULIN AND RADIATION FOR RETROPERITONEAL LIPOSARCOMA
Emile Latour
Favorite
Lau, Ching

The Jackson Laboratory for Genomic Medicine
(P 70) IDENTIFICATION OF NOVEL PROTEIN VARIANTS IN OSTEOSARCOMA TUMORS THROUGH LONG-READ RNA SEQUENCING
Ching Lau
Favorite
Lawlor, Elizabeth

Seattle Children's Research Institute
(P 330) EFFICACY OF NON-CARDIOTOXIC ANTHRACYCLINES IN EWING SARCOMA
Elizabeth Lawlor
Favorite
Lawrenz, Joshua

Vanderbilt University Medical Center
(P 73) LONGER TIME INTERVAL BETWEEN NEOADJUVANT CHEMOTHERAPY AND SURGERY IS ASSOCIATED WITH DECREASED TUMOR PERCENT NECROSIS IN OSTEOSARCOMA
Joshua Lawrenz
Favorite
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Joshua Lawrenz
Favorite
(P 264) INTRAOPERATIVE FROZEN BONE MARROW MARGINS: A HELP OR A HINDRANCE IN EWING SARCOMA RESECTION?
Joshua Lawrenz
Favorite
(P 265) IS THERE AN IDEAL STEM TO CANAL RATIO IN LOWER EXTREMITY ONCOLOGIC ENDOPROSTHESIS RECONSTRUCTION?
Joshua Lawrenz
Favorite
(P 268) LOWER TUMOR PERCENT NECROSIS IS ASSOCIATED WITH POSITIVE FINAL SURGICAL MARGINS IN OSTEOSARCOMA
Joshua Lawrenz
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Joshua Lawrenz
Favorite
(P 404) ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL FOR PATENTS WITH SOFT TISSUE SARCOMA OF THE EXTREMITY: A PROSPECTIVE, NON-RANDOMIZED, CONSECUTIVELY ENROLLED TRIAL
Joshua Lawrenz
Favorite
Lazar, Alexander

MD Anderson Cancer Center
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Alexander Lazar
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Alexander Lazar
Favorite
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Alexander Lazar
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Alexander Lazar
Favorite
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
Alexander Lazar
Favorite
Lazarides, Alexander

Moffitt Cancer Center
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
Alexander Lazarides
Favorite
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Alexander Lazarides
Favorite
(P 262) EVALUATION OF STAGED RESECTION WITH TEMPORIZING VAC OF SOFT TISSUE SARCOMAS
Alexander Lazarides
Favorite
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Alexander Lazarides
Favorite
(P 279) SIGNIFICANCE OF TIP-APEX DISTANCE IN ACTUAL AND IMPENDING PATHOLOGICAL FRACTURES OF THE PROXIMAL FEMUR
Alexander Lazarides
Favorite
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Alexander Lazarides
Favorite
Lazcano, Rossana

MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
Rossana Lazcano
Favorite
Le Cesne, Axel

Gustave Roussy
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Axel Le Cesne
Favorite
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Axel Le Cesne
Favorite
(P 181) UPDATED OVERALL SURVIVAL WITH RIPRETINIB VS SUNITINIB IN PATIENTS WITH SECOND-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR AND KIT EXON 11+17/18 MUTATIONS: CIRCULATING TUMOR DNA ANALYSIS FROM INTRIGUE
Axel Le Cesne
Favorite
Le Moli, Marialudovica

Humanitas University/IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Marialudovica Le Moli
Favorite
(P 155) PRIMARY MESENCHYMAL TUMORS OF THE HEART: A 8-YEARS, SINGLE INSTITUTION EXPERIENCE
Marialudovica Le Moli
Favorite
LeBrasseur, Nathan

Mayo Clinic
(P 200) FRAILTY ASSESSMENT IN OLDER PATIENTS RECEIVING SARCOMA THERAPY
Nathan LeBrasseur
Favorite
Ledesma, Patricio

Sofpromed
(P 234) IMMUNOSARC II MASTER TRIAL (PHASE II OF SUNITINIB AND NIVOLUMAB): RESULTS FROM THE CLEAR CELL SARCOMA (CCS) COHORT. A GEIS, ISG, AND UCL STUDY
Patricio Ledesma
Favorite
Lee, Alex

UCSF
(P 65) EPIGENETIC HETEROGENEITY AND STATE SPECIFIC TRANSCRIPTIONAL PROGRAMS DRIVE DRUG RESPONSE IN OSTEOSARCOMA
Alex Lee
Favorite
Lee, Alex

Stanford University School of Medicine
(P 143) EARLY ASSESSMENT OF DISEASE RESPONSE TO IMMUNOTHERAPY VIA CIRCULATING TUMOR DNA IN ADVANCED SOFT TISSUE SARCOMAS
Alex Lee
Favorite
lee, Dasom

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Dasom lee
Favorite
Lee, Jinhee

Lunit
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Jinhee Lee
Favorite
Lee, Kyoung Bun

Seoul National University Hospital
(P 428) OLIGOMETASTASES IN EXTREMITY SOFT TISSUE SARCOMA : SUBTYPE-SPECIFIC ANALYSES OF CHARACTERISTICS AND OUTCOMES
Kyoung Bun Lee
Favorite
Lee, Kyu Sang

Seoul National University Bundang Hospital
(P 123) ARTIFICIAL INTELLIGENCE-POWERED MITOSIS EVALUATION TO COMPLEMENT HUMAN MITOTIC RATE INTERPRETATION IN PREDICTING PROGNOSIS IN LIPOSARCOMA
Kyu Sang Lee
Favorite
Lee, Ming-Jing

National Taiwan University Hospital Hsin-Chu Branch
(P 348) EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS
Ming-Jing Lee
Favorite
Lee, Minjae

University of Texas Southwestern Medical Center
(P 417) VITAS: ATEZOLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS: AN OPEN-LABEL, PHASE I/II, SINGLE-ARM, MULTI-CENTER TRIAL IN PROGRESS
Minjae Lee
Favorite
Lee, Sang Gyu

Memorial Sloan Kettering Cancer Center
(P 302) HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS
Sang Gyu Lee
Favorite
Lee, Stella

UPMC
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Stella Lee
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Stella Lee
Favorite
Lee, Yoongyeong

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Yoongyeong Lee
Favorite
Lefler, Daniel

University of Pennsylvania
(P 397) MTOR ACTIVITY: A BIOMARKER FOR CHEMO- AND IMMUNOTHERAPY RESPONSE AND OUTCOMES IN SARCOMAS
Daniel Lefler
Favorite
Leiva, Ana Paula

Hospital Clínico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Ana Paula Leiva
Favorite
Leix, Julia

University of Pittsburgh/UPMC Children's Hospital of Pittsburgh
(P 392) ATRX LOSS IN UTERINE LEIOMYOSARCOMA IS ASSOCIATED WITH WORSE OVERALL SURVIVAL AND A DISTINCT PATTERN OF GENE EXPRESSION ACROSS SUBTYPES
Julia Leix
Favorite
Lemieux, Christopher

CHU de Quebec - Universite Laval
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Christopher Lemieux
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Christopher Lemieux
Favorite
Lemos, Maria Manuel

Instituto Português de Oncologia de Lisboa Francisco Gentil
(P 128) DYNAMIC HETEROGENEITY AMONGST LIPOSARCOMAS
Maria Manuel Lemos
Favorite
Leonard, Hugh

Chair of Trustees of the EHE Rare Cancer Charity UK, Charity Number 1162472
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Hugh Leonard
Favorite
Letson, Douglas

Moffitt Cancer Center
(P 150) MODERN BIOPSY PRACTICE PATTERNS: A SURVEY OF THE MSTS MEMBERSHIP
Douglas Letson
Favorite
(P 257) COMPARATIVE OUTCOMES OF CONSTRAINED ACETABULAR LINERS VS. DUAL MOBILITY CUPS IN COMPLEX HIP RECONSTURCTION FOR METASTATIC BONE DISEASE
Douglas Letson
Favorite
(P 263) HEMI- VS. REVERSE SHOULDER ARTHROPLASTY OUTCOMES FOLLOWING PROXIMAL HUMERAL ONCOLOGIC RESECTION
Douglas Letson
Favorite
(P 347) CAN UPFRONT RADIOTHERAPY PRECLUDE THE NEED FOR OPERATIVE STABILIZATION IN IMPENDING EXTREMITY FRACTURES FROM LUNG CANCER METASTASES?
Douglas Letson
Favorite
Levine, Nicole

Duke University Hospital
(P 16) HOW TO GROW A BONE IN 60 DAYS: EXPLORING THE UNIQUE PRO-GROWTH, ANTI-CANCER ENVIRONMENT IN ELK ANTLERS
Nicole Levine
Favorite
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Nicole Levine
Favorite
(P 142) CORE NEEDLE BIOPSY OF PERIACETABULAR CHONDROSARCOMA OFTEN RESULTS IN UNDER-GRADING BUT DOES NOT CHANGE MANAGEMENT BY EXPERIENCED ORTHOPAEDIC ONCOLOGISTS.
Nicole Levine
Favorite
(P 148) ISOCITRATE DEHYDROGENASE MUTATIONS IN CHONDROSARCOMA: A META-ANALYSIS
Nicole Levine
Favorite
Levy, Joan

Melanoma Research Alliance
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Joan Levy
Favorite
Lewandowski, Sara

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Sara Lewandowski
Favorite
Lhermitte, Benoit

University Hospital of Strasbourg and UMR CNRS 7021
(P 89) TARGETED THERAPY OF MET, TYROSINE KINASE RECEPTOR, IN PEDIATRIC HIGH-GRADE OSTEOSARCOMAS : A NEW WAY TO TREAT PATIENTS ?
Benoit Lhermitte
Favorite
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Benoit Lhermitte
Favorite
Liang, Han

Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Digestive Cancer, Tianjin; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Han Liang
Favorite
Li, Binghao

Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Binghao Li
Favorite
Li, Chia-Chen

National Taiwan University Cancer Center
(P 348) EVALUATING THE IMPACT OF BIOLOGICAL EFFECTIVE DOSE AND DELAYED RADIOTHERAPY ON THE SYNERGISTIC EFFICACY OF TRABECTEDIN IN METASTATIC SOFT TISSUE SARCOMA PATIENTS
Chia-Chen Li
Favorite
Li, Duan

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
Duan Li
Favorite
Liebner, David

The Ohio State University Comprehensive Cancer Center
(P 207) PATIENT-REPORTED GLOBAL HEALTH PREDICTS ADVERSE HEALTH OUTCOMES IN PATIENTS WITH ADVANCED SARCOMA
David Liebner
Favorite
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
David Liebner
Favorite
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
David Liebner
Favorite
Lieu, Christopher

University of Colorado
(P 95) THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN PATIENTS WITH CHONDROSARCOMA: UPDATED RESULTS FROM A PHASE 1 STUDY
Christopher Lieu
Favorite
Li, George

Memorial Sloan Kettering Cancer Center
(P 101) AN OPEN LABEL PHASE IIA STUDY EVALUATING THE PRELIMINARY EFFICACY OF INTRATUMORAL TIGILANOL TIGLATE (TT) IN ADVANCED AND/OR METASTATIC SOFT TISSUE SARCOMA (STS, NCT05755113)
George Li
Favorite
Li, Hui

Fujian Cancer Hospital
(P 409) PHASE 2 STUDY EVALUATING SURUFATINIB IN PATIENTS WITH OSTEOSARCOMA AND SOFT TISSUE SARCOMA WHO HAVE FAILED STANDARD CHEMOTHERAPY
Hui Li
Favorite
Li, Jian

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute Beijing 100142, P. R. China
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
Jian Li
Favorite
li, jiazheng

Peking University Cancer Hospital
(P 180) TUMOR VASCULAR SIGN IN THE RESPONSE ASSESSMENT OF GASTROINTESTINAL STROMAL TUMOR TREATED WITH RIPRETINIB: A MULTICENTER STUDY
jiazheng li
Favorite
Li, Jing

Karmanos Cancer Institute
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Jing Li
Favorite
Li, Jing

Department of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
(P 93) THE PROTEOGENOMIC SUBTYPING OF OSTEOSARCOMA
Jing Li
Favorite
Li, Jinxiu

University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Jinxiu Li
Favorite
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Jinxiu Li
Favorite
Li, Li

Department of Orthopaedics, University of Utah
(P 332) ENHANCING THERAPEUTIC EFFICACY IN SYNOVIAL SARCOMA BY TARGETING P53-MDM2 AXIS AND HDAC PATHWAYS
Li Li
Favorite
(P 343) TLE1 DISRUPTION DOES NOT IMPEDE SYNOVIAL SARCOMAGENESIS
Li Li
Favorite
Lillemoe, Heather

MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Heather Lillemoe
Favorite
Li, Luyuan

University of Miami
(P 58) COMBINATORY THERAPIES UTILIZING INHIBITION OF CARBONIC ANHYDRASE IX TO POTENTIATE RESPONSE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Luyuan Li
Favorite
Lim, Allison

SpringWorks Therapeutics, Inc.
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Allison Lim
Favorite
Lim, Ratana

WEHI - Walter and Eliza Hall Institute of Medical Research
(P 325) CAN PROTEOMICS PREDICT METASTATIC RELAPSE IN LEIOMYOSARCOMA? DEVELOPMENT OF AN 8 PROTEIN SIGNATURE IN A >350 SAMPLE STUDY INCLUDING A VALIDATION COHORT
Ratana Lim
Favorite
Lim, Terry

Monash University
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Terry Lim
Favorite
Linardic, Corinne

Duke University School of Medicine
(P 287) AN INTERNATIONAL SURVEY OF PROVIDER PRACTICES REGARDING BONE MARROW SAMPLING VERSUS [18F] FDG PET/CT IN THE DIAGNOSTIC EVALUATION OF BONE MARROW METASTASIS IN PEDIATRIC RHABDOMYOSARCOMA
Corinne Linardic
Favorite
Lin, Chia-Chi

National Taiwan University Hospital
(P 37) HEALTH-RELATED QUALITY OF LIFE FROM A PHASE 4 STUDY TO EVALUATE DISCONTINUATION AND RECHALLENGE OF PEXIDARTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR PREVIOUSLY TREATED WITH PEXIDARTINIB
Chia-Chi Lin
Favorite
Lind Nielsen, Christian

Department of Orthopedics, Aarhus University Hospital
(P 104) CIRQUESARC: A NATIONAL PROSPECTIVE OBSERVATIONAL STUDY OF CIRCULATING TUMOR DNA AND QUALITY OF LIFE IN PATIENTS WITH SARCOMA – PRELIMINARY RESULTS FROM THE SURGICAL COHORT
Christian Lind Nielsen
Favorite
Lindner, Lars

Department of Medicine III, LMU University Hospital, LMU Munich
(P 410) PHASE I STUDY OF THE001 (DPPG2-TSL-DOX) COMBINED WITH REGIONAL HYPERTHERMIA IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOFT TISSUE SARCOMA
Lars Lindner
Favorite
Lindsay, Sarah

Oregon Health & Science University
(P 34) DESMOID TUMOR COHORT CREATION AND CHARACTERISTICS IN THE VETERANS AFFAIRS (VA) NATIONAL DATABASE
Sarah Lindsay
Favorite
(P 223) ASSOCIATION OF POSTOPERATIVE INFECTION (POI) WITH SOFT TISSUE SARCOMA (STS) RESECTION OUTCOMES
Sarah Lindsay
Favorite
(P 285) A NOVEL METHOD TO PREDICT HEIGHT AT SKELETAL MATURITY IN PEDIATRIC SARCOMA PATIENTS
Sarah Lindsay
Favorite
Lindskog, Stefan

Sahlgrenska University Hospital
(P 170) GASTRIN RELEASING PEPTIDE RECEPTOR EXPRESSION IN GASTROINTESTINAL STROMAL TUMORS (GIST)
Stefan Lindskog
Favorite
Lingad, Allyssa

Sarcoma Oncology Center
(P 248) TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA AND LIPOSARCOMA (NCT # 03886311)
Allyssa Lingad
Favorite
Lin, Jian-Hua

The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Jian-Hua Lin
Favorite
Lin, Ran

Tel Aviv Soursky medical center
(P 350) MONITORING CHANGES IN FEMORAL BONE STRENGTH IN PATIENTS WITH METASTATIC BONE DISEASE TREATED WITH RADIATION THERAPY
Ran Lin
Favorite
Lipplaa, Astrid

Leiden University Medical Center
(P 42) RANKL-INHIBITION FOR GIANT CELL LESIONS OF THE JAW: A RETROSPECTIVE COHORT ANALYSIS
Astrid Lipplaa
Favorite
Li, Qian

University of California Davis School Medicine
(P 205) MULTI-MODAL TREATMENT IS ASSOCIATED WITH IMPROVED SURVIVAL IN AYA PATIENTS WITH METASTATIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Qian Li
Favorite
(P 356) RADIATION PRACTICE PATTERNS AND OUTCOMES IN ADOLESCENT YOUNG ADULT PATIENTS WITH VISCERAL NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA
Qian Li
Favorite
Liu, Hongrui

University of Calgary
(P 289) APPLICATION AND ANALYSIS OF SPATIAL TRANSCRIPTOMIC PROFILING TO CLINICAL ALVEOLAR SOFT PART SARCOMA SAMPLES TO UNDERSTAND IMMUNOTHERAPY-RELEVANT VARIABLES
Hongrui Liu
Favorite
Liu, Kunpeng

Department of Anesthesiology, Peking University International Hospital
(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Kunpeng Liu
Favorite
(P 377) INCIDENCE, RISK FACTORS, AND EFFECT ON 60-DAYS SURVIVAL OF ACUTE KIDNEY INJURY OCCURRED WITHIN 7 DAYS AFTER SURGERY IN ELDERLY PATIENTS WITH RETROPERITONEALL TUMORS: A RETROSPECTIVE COHORT STUDY
Kunpeng Liu
Favorite
(P 379) KEY POINTS OF ANESTHESIA MANAGEMENT AND PROGNOSIS ANALYSIS OF ELDERLY PATIENTS WITH RETROPERITONEAL TUMOR
Kunpeng Liu
Favorite
Liu, Renyan

Dana-Farber Cancer Institute
(P 402) A PILOT STUDY OF BTX-A51 IN PATIENTS WITH METASTATIC AND/OR RECURRENT LIPOSARCOMAS CHARACTERIZED BY MDM2 AMPLIFICATIONS
Renyan Liu
Favorite
Liu, Tracy

West Virginia University
(P 342) THE ROLE OF MYELOPEROXIDASE IN SARCOMA TREATMENT
Tracy Liu
Favorite
Liu, Yu-Tao

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Yu-Tao Liu
Favorite
Liverani, Chiara

Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" IRST IRCCS, Preclinic and Osteoncology Unit, Meldola, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Chiara Liverani
Favorite
Livingston, J. Andrew

The University of Texas MD Anderson Cancer Center, Houston, TX, USA
(P 49) A WORKING GROUP FOR THE DEVELOPMENT OF A CLINICAL FRAMEWORK THAT STRATIFIES OSTEOSARCOMA PATIENTS USING BIOMARKERS OF CLINICAL RISK AND BIOLOGY
J. Andrew Livingston
Favorite
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
J. Andrew Livingston
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
J. Andrew Livingston
Favorite
(P 396) LONG-TERM FOLLOW-UP EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
J. Andrew Livingston
Favorite
Li, Wei

Department of Medical Oncology, Zhongshan Hospital, Fudan University,Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Wei Li
Favorite
Li, William

University of Pittsburgh Medical Center
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
William Li
Favorite
Li, Yi Xin

Singapore General Hospital
(P 370) DEFYING NORMS - CENTRALIZATION OF SARCOMA CARE ON AN ISLAND NATION
Yi Xin Li
Favorite
Li, Yi Xin

Duke NUS Medical School
(P 375) FROM SAPLING TO SHADE: GROWTH OF A HIGH VOLUME ASIAN TERTIARY SARCOMA SPECIALISED CENTRE
Yi Xin Li
Favorite
Li, Yi-Jia

Beckman Research Institute at City of Hope Cancer Center
(P 07) DIRECTLY TARGETING CIC-DUX4 FUSION AND MYC ONCOPROTEINS FOR UNDIFFERENTIATED ROUND CELL SARCOMAS
Yi-Jia Li
Favorite
Li, Yuan

Beijing Jishuitan Hospital, Capital Medical University
(P 407) LONG-TERM EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE.
Yuan Li
Favorite
Li, Yuezhe

Metrum Research Group
(P 116) QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF MIPASETAMAB UZOPTERINE INTEGRATES KNOWLEDGE AND DEFINES DOSING STRATEGY FOR PATIENTS WITH SARCOMA
Yuezhe Li
Favorite
Ljevar, Silva

Unit of Biostatistics for Clinical Research Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Silva Ljevar
Favorite
(P 111) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF SPINDLE CELL/ SCLEROSING RHABDOMYOSARCOMA (S-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Silva Ljevar
Favorite
Ljevar, Silva

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 429) PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA TREATED WITH SIROLIMUS: OUTCOME FOLLOWING SIROLIMUS DISCONTINUATION.
Silva Ljevar
Favorite
Lobmaier, Ingvild

Oslo University Hospital
(P 40) PEGYLATED LIPOSOMAL DOXORUBICIN IN SYMPTOMATIC DESMOID TUMOR
Ingvild Lobmaier
Favorite
Lobner, Amy

The Osteosarcoma Institute
(P 408) OSTEOMYC: A PHASE 2 PILOT STUDY TO EVALIATE THE SAFETY AND THE ANTITUMOR ACTIVITY OF THE MYC INHIBITOR OMO-103 ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH ADVANCED HIGH GRADE OSTEOSARCOMA
Amy Lobner
Favorite
Locatelli, Franco

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Franco Locatelli
Favorite
Loferer, Hannes

iOmx AG
(P 337) OMX-0407 A NOVEL SPECTRUM-SELECTIVE SMALL MOLECULE KINASE INHIBITOR IS ACTIVE IN THE TREATMENT OF ANGIOSARCOMA
Hannes Loferer
Favorite
Logie, Natalie

Tom Baker Cancer Center
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Natalie Logie
Favorite
Lohse, Ines

University of Pittsburgh
(P 51) ASSESSING THE IN VIRTO EFFICACY OF DISULFIRAM AND ENZALUTAMIDE COMBINATION THERAPY IN METASTATIC OSTEOSARCOMA
Ines Lohse
Favorite
(P 117) THE TUMOR IMMUNE MICROENVIRONMENT OF DEDIFFERENTIATED SARCOMAS: DIGITAL SPATIAL PROFILING SHOWS IMMUNE TRANSCRIPTIONAL DIFFERENCES BETWEEN DEDIFFERENTIATED LIPOSARCOMA AND CHONDROSARCOMA
Ines Lohse
Favorite
(P 240) INVESTIGATING MACROPHAGE POPULATION VARIABILITY IN METASTATIC SARCOMA SAMPLES
Ines Lohse
Favorite
(P 256) CHARACTERIZING ORTHOPAEDIC ONCOLOGIC POLYTRAUMAS: A COMPARISON OF PATIENTS UNDERGOING OPERATIVE FIXATION OF MULTIPLE LESIONS WITH THOSE WITH SOLITARY LESIONS
Ines Lohse
Favorite
(P 258) COMPARING OUTCOMES FOLLOWING INTRALESIONAL VERSUS WIDE RESECTION PROCEDURES IN THE TREATMENT OF RENAL CELL CARCINOMA BONE METASTASES
Ines Lohse
Favorite
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Ines Lohse
Favorite
Loidl, Verena

Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Faculty of Medicine, LMU Munich, MPH
(P 201) GLOBAL CROSS-SECTIONAL SURVEY ON SARCOMA DIAGNOSIS PATHWAY: A CURRENT STATE ANALYSIS
Verena Loidl
Favorite
Lokshin, Anna
(P 353) PREDICTING WOUND COMPLICATIONS FOLLOWING SOFT-TISSUE SARCOMA RESECTION AMONG PATIENTS WHO RECEIVED PRE-OPERATIVE RADIATION
Anna Lokshin
Favorite
Long, Chris

Stanford University
(P 74) MATRIX DENSITY INDUCES CHEMORESISTANCE WITHIN A TISSUE-ENGINEERED MODEL OF OSTEOSARCOMA
Chris Long
Favorite
Lopez, Ann

Clear Cell Sarcoma Foundation
(P 189) CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS
Ann Lopez
Favorite
Lopez-Fuentes, Eunice

UCSF
(P 65) EPIGENETIC HETEROGENEITY AND STATE SPECIFIC TRANSCRIPTIONAL PROGRAMS DRIVE DRUG RESPONSE IN OSTEOSARCOMA
Eunice Lopez-Fuentes
Favorite
LoRusso, Patricia

Yale University School of Medicine, Yale Cancer Center
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Patricia LoRusso
Favorite
LOZANO LOMINCHAR, PABLO

Memorial Sloan Kettering Cancer Center
(P 380) MULTIDISCIPLINARY MANAGEMENT OF INTRA-ABDOMINAL DESMOID-TYPE FIBROMATOSIS: A 30-YEARS EXPERIENCE
PABLO LOZANO LOMINCHAR
Favorite
Lozano-Calderon, Santiago A.

Massachusetts General Hospital, Harvard Medical School
(P 63) DOES TUMOR NECROSIS IMPACT PROGNOSIS IN CHONDROBLASTIC AND OSTEOBLASTIC OSTEOSARCOMA? A STUDY FROM A LARGE TERTIARY CARE ACADEMIC CENTER
Santiago A. Lozano-Calderon
Favorite
(P 100) ADVANCING PROGNOSTICS IN ONCOLOGY: MACHINE LEARNING MODELS FOR PREDICTING 2-YEAR AND 5-YEAR SURVIVAL RATES IN PATIENTS WITH UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Santiago A. Lozano-Calderon
Favorite
(P 107) DOES THE USE OF ADJUVANT CHEMOTHERAPY IN LOCALIZED, RESECTABLE SOFT TISSUE SARCOMA LEAD TO BETTER SURVIVAL OUTCOMES? - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Santiago A. Lozano-Calderon
Favorite
(P 108) FIXATION OF IMPENDING OR PATHOLOGIC FRACTURES DUE TO METASTATIC DISEASE WITH CARBON FIBER INTRAMEDULLARY NAILS-A PROPENSITY-SCORE MATCHED COST ANALYSIS
Santiago A. Lozano-Calderon
Favorite
(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Santiago A. Lozano-Calderon
Favorite
Lubovsky, Omri

Orthopedics, Barzilai Medical Center
(P 182) A NOVEL MODEL FOR THE DIRECT REFERRAL OF ONCOLOGIC PATIENTS IN A PUBLIC HEALTH CARE SYSTEM
Omri Lubovsky
Favorite
Lucarelli, Enrico

Istituto Ortopedico Rizzoli IRCCS, Osteoncology- Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, Bologna, Italy
(P 336) IMPROVEMENT OF PHOTODYNAMIC THERAPY IN SARCOMA: IN VITRO VALIDATION ON OSTEOSARCOMA AND MYXOFIBROSARCOMA
Enrico Lucarelli
Favorite
Lucatelli, Maria Victoria

Pharmacology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 431) REAL-WORLD EXPERIENCE OF EFFICACY AND TOLERABILITY OF CONTINUOS INFUSION IFOSFAMIDE AMONG ADVANCED SOFT TISSUE AND BONE SARCOMAS PATIENTS: A SINGLE CENTRE RETROSPECTIVE COHORT.
Maria Victoria Lucatelli
Favorite
Lui, Darren

St. George’s Hospital
(P 261) EVALUATION OF CT ARTIFACTS AFTER SPINAL OLIGOMETASTATIC DISEASE RESECTION AND RECONSTRUCTION: A COMPARATIVE STUDY OF CARBON-FIBER VS. TITANIUM IMPLANTS
Darren Lui
Favorite
Luiz Cunha Martins, Cicero

Latin American Cooperative Oncology Group
(P 192) CURRENT SCENARIO OF SARCOMA CLINICAL TRIALS IN SOUTH AMERICA: A REPORT BY THE LACOG SARCOMA GROUP
Cicero Luiz Cunha Martins
Favorite
(P 216) SARCOMA CARE PATHWAYS AND MULTIDISCIPLINARY TUMOR BOARDS IN LATIN AMERICA: AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Cicero Luiz Cunha Martins
Favorite
(P 217) SARCOMA DRUG APPROVALS IN LATIN AMERICA COMPARED TO THE FDA AND EMA: AN ANALYSIS BY THE LACOG SARCOMA GROUP
Cicero Luiz Cunha Martins
Favorite
(P 219) SOCIAL MEDIA USE AMONG MEDICAL PROFESSIONALS THAT TREAT PATIENTS WITH SARCOMA IN LATIN AMERICA: RESULTS OF AN INTERNATIONAL SURVEY BY THE LACOG SARCOMA GROUP
Cicero Luiz Cunha Martins
Favorite
Lum, Lotus

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Lotus Lum
Favorite
Lunt, Colin

Adaptimmune
(P 202) IMPACT OF AFAMI-CEL ON THE HEALTH STATE OF PATIENTS WITH ADVANCED SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA: COHORT 1 OF SPEARHEAD-1
Colin Lunt
Favorite
Luo, Cheng-Hua

Peking University People's Hospital
(P 186) ANALYSIS OF FACTORS INFLUENCING POSTOPERATIVE VENOUS THROMBOEMBOLISM FORMATION IN PATIENTS WITH MASSIVE BLOOD LOSS DURING RETROPERITONEAL TUMOR RESECTION
Cheng-Hua Luo
Favorite
(P 377) INCIDENCE, RISK FACTORS, AND EFFECT ON 60-DAYS SURVIVAL OF ACUTE KIDNEY INJURY OCCURRED WITHIN 7 DAYS AFTER SURGERY IN ELDERLY PATIENTS WITH RETROPERITONEALL TUMORS: A RETROSPECTIVE COHORT STUDY
Cheng-Hua Luo
Favorite
Luo, Chongliang

Washington University in St Louis
(P 81) OUTCOMES DATA FOR OSTEOSARCOMA PATIENTS OVER AGE 60
Chongliang Luo
Favorite
(P 187) BRIDGING THE GAP: UNDERSTANDING THE CURRENT TREATMENT RESPONSES TO ENHANCE THE STANDARD OF CARE AND OUTCOMES FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Chongliang Luo
Favorite
Luo, Leo

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Leo Luo
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Leo Luo
Favorite
Luo, Rong-Kui

Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Rong-Kui Luo
Favorite
Lupo, Philip

Texas Children's Cancer Center, Epidemiology Program, Baylor College of Medicine
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Philip Lupo
Favorite
Lusi, Stefano

IRCCS Humanitas Research Hospital
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Stefano Lusi
Favorite
Lu, Weiqi

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Weiqi Lu
Favorite
lv, yu

Shanghai General Hospital, School of Medicine Shanghai Jiao Tong University
(P 48) A SINGLE-ARM, OPEN-LABEL CLINICAL STUDY OF OVV-01 ONCOLYTIC VIRUS INJECTION AS MONOTHERAPY OR IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS FOR ADVANCED SOLID TUMOR PATIENTS
yu lv
Favorite
(P 90) TARGETING HIGH RISK MYC- AMPLIFIED OSTEOSARCOMA BY AURORA KINASE INHIBITOR--RESULT FROM A NGS BASED UMBRELLA TRIAL
yu lv
Favorite
Lyle, Alfred

University of California- Santa Cruz
(P 295) DEFINING OSTEOSARCOMA HETEROGENEITY: CONSENSUS CLUSTERING REVEALS GENE EXPRESSION SUBTYPES
Alfred Lyle
Favorite
Lynch, Carmel

Adcendo ApS
(P 331) EFFICACY OF NOVEL UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN TARGETED ANTIBODY-DRUG CONJUGATES IN PATIENT-DERIVED XENOGRAFTS OF SOFT TISSUE SARCOMA
Carmel Lynch
Favorite
Lyu, Heather

MD Anderson Cancer Center
(P 130) HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RESECTABLE RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA (DDLPS) TREATED WITH NEOADJUVANT CHECKPOINT BLOCKADE IN A RANDOMIZED PHASE II CLINICAL TRIAL.
Heather Lyu
Favorite
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Heather Lyu
Favorite